ReachRxResearch
Home
Research
Sign Up
Study limitation
Back to Research Hub
  1. Home
  2. Research Hub
  3. Study limitation

Treatment Choice and Cardiovascular Risk in Chronic Spontaneous Urticaria

Study limitation reported by the research below: “Funding came partly from Novartis (omalizumab manufacturer), and one author received Novartis funding to support this study — findings favoring omalizumab should be interpreted with this conflict in mind.”

Papers